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T e emphasis on the internal validity of clinical research in evidence-based medicine has had the ef ect of making the quality of the "answer" more important than the appropriateness of the "question. " In the pursuit of a valid answer, randomized controlled trials (RCTs) that emphasize ef cacy under nearideal conditions have become a preferred strategy for both regulators (who need to approve medicines and devices for clinical use) and investigators (who design trials). When "ef cacy trials" dominate, and studies that ref ect real-world use of the treatment are reduced in importance, a surprising collateral ef ect is that the value attributed to the patient's experience with their disease and its treatment is diminished.
Fundamentally, there is no bright line that separates ef cacy studies from those that assess ef ectiveness. With the right methods, observational studies can be used to assess treatment benef ts. And RCTs exist on a continuum from those that emphasize ef cacy (explanatory trials) to those that emphasize ef ectiveness (practical or pragmatic trials). In this Focus, we illustrate the central importance of the research question in the design of clinical studies to get the right answer for patients and physicians.
RIGHT QUESTIONS FOR RCTS
Numerous RCTs of the asthma drug montelukast had shown that it was inferior to inhaled corticosteroids as a f rst-line treatment for asthma control and also inferior to long-acting beta agonists (LABAs) as a second-line "add-on" therapy. Montelukast is an oral medicine with higher adherence than that of inhaled agents when used in real-world settings. However, as of en occurs in short-term (~6 months), placebocontrolled trials, patients were able to maintain high levels of adherence to all treatments, therefore obscuring the inf uence of adherence levels on the ef ectiveness of treatment. Furthermore, the RCT investigators chose to def ne the primary study outcomes as changes in lung function, a hard physiological measure.
A study that illustrates the apparent advantage of inhaled steroids and LABAs comes from the results of an ef cacy RCT in which montelukast was compared with beclamethasone and placebo (1) . In this study, both montelukast and beclamethasone were superior to placebo [in improvements in forced expiratory volume in 1 second (FEV1)], and beclamethasone was superior to montelukast. Despite these f ndings, montelukast remains popular with patients and physicians. Evidence to support this popularity was generated when montelukast was tested in real-world ef ectiveness studies by using a pragmatic randomized trial design (2) . In these real-world studies, montelukast was just as ef ective as both inhaled corticosteroids and LABAs. What was dif erent?
T e real-world studies enrolled patients with asthma who were more like those seen in actual clinical practice; had lower adherence rates that ref ect levels seen commonly in customary care, not those artifcially achieved in placebo controlled trials; and measured clinical end points such as symptoms, function, and well-being. When tested rigorously in this setting, the adherence advantage of montelukast as a oncedaily oral medication was evident. T us, what was dif erent between the traditional ef cacy RCTs and the pragmatic studies of montelukast is that they asked dif erent questions about the performance of the drug in dif erent settings.
T e choice of the question is closely linked to the features that distinguish efcacy from ef ectiveness trials. Four features distinguish the traditional ef cacy RCT: (i) populations are homogeneous, (ii) the spectrum of the medical illness is of en narrowly def ned, (iii) the new treatment requires strict guidelines for use of the evaluated medicine and concomitant therapies, and (iv) "hard" end points (death and major 
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DESIGN FEATURES
T e only feature of the RCT that cannot be included in observational studies is the use of randomization to assign treatment. Investigators interested in RCTs evaluating clinical ef ectiveness can modify other design features so as to mimic clinical practice more closely. Increasingly, we are seeing modif ed RCT designs, such as clusterbased trials and point-of-care randomization. Other modif cations to RCTs include distributing medicines to community pharmacies as well as obtaining data from routine clinical care documented in electronic health records. All of these innovations are helping to embed trials more directly into real-world settings.
Not surprisingly, RCTs frequently deviate from this real-world design, so that the intended evaluation of ef cacy is of en not achieved. When RCTs follow patients for prolonged durations, for example, the investigators of en are lef to struggle with sources of bias that are commonplace in observational studies. Consider the Women's Health Trial that randomized 16,000 postmenopausal women to either hormone replacement therapy (HRT) or placebo and planned an 8-year follow-up to test whether HRT would improve certain clinical outcomes. T e study was stopped early when an increased risk was observed for coronary heart disease among women assigned to receive HRT (3) .
T e interpretation of these results was complicated when it was reported that treatment was discontinued, and blinding was broken for nearly half of the HRT users but only a small percentage of the placebo users. T e changes in treatment occurred mostly to manage vaginal bleeding that developed as the trial progressed among women assigned to estrogen therapy. But the loss of blinding created unanticipated problems in detection bias and in the adjudication of end points (because patients and physicians were unblinded by a treatment side ef ect), and the changes in treatment assignment meant that the planned intent-to-treat analysis no longer could answer the question that had been originally proposed (4) . Instead of answering a question of the efcacy of estrogens on cardiovascular disease (CVD), the study was now a test of initiating a treatment that many patients had changed during follow-up.
Although it is possible to debate the interpretation of the HRT trial results, it is clear that RCTs that follow patients for prolonged time periods may lose the benef ts that ordinarily accrue to the design of efcacy RCTs and may f nd that they are answering a question dif erent from the one that motivated the trial. Newer approaches use analytical methods commonly applied to observational studies that account for changes in medical conditions and treatments over time and strengthen the analysis of such long-term RCTs.
RIGHT QUESTIONS FOR OBSERVATIONAL STUDIES
For many years, observational studies had suggested that estrogen users had a decreased risk of cardiovascular mortality and ischemic heart disease. T e studies that reported this apparent decreased risk compared women who were currently using estrogens with nonusers and estimated that estrogen users had a 25 to 35% reduction in risk of CVD (5). However, when the ef ect of estrogen on CVD was evaluated in an RCT, as noted above, estrogen users had a 20% increased risk of CVD (6) . What could explain this discrepancy?
T e customary explanation is one familiar to all clinical investigators: confounding. In this instance, the bias was postulated because women who chose to use estrogens had a lower risk of CVD at baseline than that of women who were nonusers. Investigators were aware of this potential bias and took steps in design (matching and similar tactics) and analysis (multivariate adjustment) to mitigate these dif erences. But as of en happens, such ef orts were considered insuf cient, and "residual confounding" was believed to have led to erroneous conclusions. T e collateral damage from this study was the conclusion that observational studies are unable to provide reliable and accurate estimates of the ef ects of treatment on disease outcomes.
Hernan and colleagues challenged the suggestion that discrepancies in results between the RCTs and the observational studies were explained with residual confounding. In their analysis, the authors pointed out that the RCT and the observational study had asked dif erent questions. Whereas the observational study had compared current users of estrogens with nonusers, the RCT compared new users of estrogens with nonusers. To prove the point, Hernan and colleagues reanalyzed a large observational cohort (Nurses Health Study) and reported similar results to the RCT when both types of studies de% ned treatment based on a new user de% nition (7) . T e choice of current users in observational studies is not helpful because it does not indicate what would happen if patients started or stopped a treatment. For this reason, focusing on new users, as is done in RCTs, is preferred in the design of observational studies.
T e results of observational studies can be distorted if the indication for treatment creates baseline inequalities in the compared groups. T is potential bias is avoided when randomization is used to assign treatment. Fortunately, newer approaches to the design and analysis of observational research can mitigate this bias. Other potential sources of bias in observational research, such as losses to follow-up, variations in adherence to treatment, or problems in adjudication of outcomes, are shared in common with RCTs and require careful consideration in design to avoid misleading results.
RIGHT QUESTIONS FOR PATIENTS
When investigators design studies, they often focus on whether the medicine improves survival or reduces some "hard" physiological measure, such as lung spirometry. Although survival and other hard clinical outcomes are important to patients, they also want to know whether they will feel better and can do more-an emphasis on patient experience that is central to the mission of Patient-Centered Outcomes Research Institute (PCORI) (www.pcori.org).
Companies responsible for developing new drugs are getting the patient-focused message, as is the U.S. Food and Drug Administration (FDA), which is responsible for approving new drugs. In November 2011, the FDA approved ruxolitinib to treat FOCUS myelo% brosis based on two phase III trials. Reduction in spleen volume was the primary end point in both trials, but demonstrating that the medicines both reduced spleen volume and improved patients' symptoms was decisive in the FDA's decision to grant approval to ruxolitinib. An FDA of cial involved in the regulatory decision stated, "[Patient symptoms] was a secondary endpoint, but in our mind this is why we gave the application full approval" (8) .
T e increasing focus on the patient experience will need to be accompanied by an increasing emphasis on the validity and reliability of patient-based end points. T e American Heart Association recently issued a Scienti% c Statement on the Importance of Measuring Patient Reported Health Status (symptom burden, functional status, and health-related quality of life) (9) . T e American Society of Clinical Oncology recently draf ed recommendations to "raise the bar" for clinical trials in an ef ort to inspire patients and investigators to demand more from clinical trials, to focus on what is clinically meaningful to the patient, and to "vote with your feet" by only participating in trials that evaluate the impact of treatment on the experience of the patient with their illness and its therapy (10) . Hardening sof er data captured from the patient experience is a fundamental requirement to ensure that patients and physicians are guided by evidence that is both true and apposite for the clinical circumstances.
QUALITY OF THE QUESTION
For too long, the design of clinical research has been driven by the goals of the investigator to get the unbiased right answer, even at the expense of the importance or applicability of the study results. T anks to advances both in research methods and the increasingly prominent voice of the patient, there is a long-overdue new emphasis on the quality of the question. But much more needs to be done. Randomized trials to assess the ef cacy of treatment will continue to be needed to demonstrate whether a medicine or device can work under ideal circumstances. T ese trials can be strengthened further by more substantive attention to methodological considerations such as more patient-relevant outcomes, more inclusive study populations, and the use of concomitant therapies. But these modi% -cations, as valuable as they would be, will not substitute for the design and conduct of studies that measure the ef ectiveness of medicines as they are used in real-world, complex settings. Randomized trials have an important role to play in the evaluation of the ef ectiveness of treatment as used in clinical practice. Innovative approaches, including adaptive trial design and Webbased RCTs, promise to advance the scienti% c basis and utility of clinical research.
As new medicines are developed with dosing pro% les that enable higher levels of adherence than have been possible to date, the right question for patients will be how treatment outcomes vary according to levels of adherence. In the example of montelukast in real-world studies, adherence was less (65%) than we would like to achieve, although better than adherence levels observed for inhaler-administered medicines, such as corticosteroids and LABA (45%) (2) . A new focus on adherence will encourage the development of programs that improve both adherence and the ef ectiveness of new medicines. It will not be suf cient to implement such programs without also conducting studies that assess their impact on patient outcomes. Investigators and patients will need to work together to measure relevant patient outcomes in realworld settings.
